



DRAFT MEDIA RELEASE

FOR IMMEDIATE RELEASE

MR# 2019057

DATE: 3 September 2019

RE: September declared Prostate Cancer Awareness Month in Town of Amherst

AMHERST, Nova Scotia – Mayor David Kogon has declared the month of September Prostate Cancer Awareness Month in the Town of Amherst.

“Prostate cancer is the most common cancer among Canadian men,” Kogon said as he signed the proclamation on Sept. 3, 2019. “The survival rate for prostate cancer is nearly 100 per cent when detected early, yet statistics provided by Prostate Cancer Canada indicate 11 Canadian men die from prostate cancer every day.

“The town wants to help reduce that figure. That is why we’re fully supporting Prostate Cancer Canada’s attempts to raise awareness of this disease. By raising awareness, we hope it will lead to more screening and the early detection that saves lives.”



Mayor David Kogon signs a proclamation declaring September as Prostate Cancer Awareness Month in the Town of Amherst. (Tom McCoag / Town of Amherst)

Data provided by Prostate Cancer Canada indicates one in seven Canadian men will be diagnosed with the disease and while the survival rate is nearly 100 per cent when there is early detection, three out of four men will die if the cancer is found late.

According to the organization’s website, men over the age of 50, black men and those with a family history of the disease are at a greater risk of getting prostate cancer. Signs and symptoms include difficulty urinating, the urgent need to urinate, frequent urination - especially at night, burning or pain when urinating, the inability to urinate and/or difficulty in starting or



stopping urine flow. Other signs include painful ejaculation and blood in the urine or semen.

The site indicates early detection is important and the PSA test is often the first test used in the detection of prostate cancer. Other tests can include a digital rectum exam, a biopsy and a MRI.

Treatment, according to the website, can include active surveillance, radical prostatectomy, radiation therapy, hormone therapy and chemotherapy. The treatment an individual will be determined following a discussion with the individual's healthcare team.

-30-

Direct Inquiries to:
Tom McCoag
Corporate Communications Officer
902-694-6265
tmccoag@amherst.ca

